Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1993-8-19
pubmed:abstractText
The present study was designed to characterize the antinociception produced by the administration of a potent muscarinic agonist into the intrathecal space of the lumbar spinal cord of male Sprague-Dawley rats. Seven days after surgical implantation of intrathecal catheters, animals were injected with graded doses of (+)-cis-methyldioxolane. (+)-cis-Methyldioxolane produced hot-plate and tail-flick antinociception for up to 90 min, peaking 5 to 30 min after injection. The dose of (+)-cis-methyldioxolane that inhibited nociception by 50% was 12 nmol in both the hot-plate and tail-flick tests. This antinociception was not accompanied by a general depression of other spontaneous motor responses. The tissue concentration of (+)-cis-methyl-dioxolane in the lumbar spinal cord present at the time of maximal hot-plate and tail-flick antinociception was approximately 12 microM. In similarity to (+)-cis-methyldioxolane, intrathecally administered (+)-muscarine also produced strong hot-plate and tail-flick antinociceptive responses. In contrast, intrathecally administered N-methylcarbachol, a nicotinic agonist, had no effect on nociception. Five-minute pretreatment with graded doses of pirenzepine, methoctramine, idazoxan, LY53857, or S-(-)-zacopride each significantly antagonized hot-plate and tail-flick antinociception produced by 37.5 nmol of (+)-cis-methyldioxolane in a dose-related manner with median effective antagonist doses in the range of 0.4 to 2.2 nmol. Intrathecal pretreatment with graded doses of prazosin or naloxone enhanced the antinociception produced by (+)-cis-methyldioxolane in the tail-flick but not the hot-plate tests. Intrathecal vehicle, S(-)-propranolol or mecamylamine did not alter (+)-cis-methyldioxolane-induced antinociception. The data suggest that the antinociceptive responses produced by intrathecally administered (+)-cis-methyldioxolane involve the stimulation of muscarinic M1 and/or M2 cholinergic receptors, and may also involve activation of alpha-2 adrenergic, 5-hydroxytryptamine1c/2 and 5-hydroxytryptamine3 serotonergic receptor systems at the level of the lumbar cord.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/2-methyldioxolane, http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Carbachol, http://linkedlifedata.com/resource/pubmed/chemical/Diamines, http://linkedlifedata.com/resource/pubmed/chemical/Dioxolanes, http://linkedlifedata.com/resource/pubmed/chemical/Mecamylamine, http://linkedlifedata.com/resource/pubmed/chemical/Muscarine, http://linkedlifedata.com/resource/pubmed/chemical/N-methylcarbamylcholine, http://linkedlifedata.com/resource/pubmed/chemical/Parasympathomimetics, http://linkedlifedata.com/resource/pubmed/chemical/Pirenzepine, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, alpha, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Muscarinic, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Opioid, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Serotonin, http://linkedlifedata.com/resource/pubmed/chemical/methoctramine
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0022-3565
pubmed:author
pubmed:issnType
Print
pubmed:volume
266
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
329-38
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:8101218-Adrenergic alpha-Antagonists, pubmed-meshheading:8101218-Analgesia, pubmed-meshheading:8101218-Animals, pubmed-meshheading:8101218-Carbachol, pubmed-meshheading:8101218-Diamines, pubmed-meshheading:8101218-Dioxolanes, pubmed-meshheading:8101218-Dose-Response Relationship, Drug, pubmed-meshheading:8101218-Drug Interactions, pubmed-meshheading:8101218-Injections, Spinal, pubmed-meshheading:8101218-Male, pubmed-meshheading:8101218-Mecamylamine, pubmed-meshheading:8101218-Muscarine, pubmed-meshheading:8101218-Nociceptors, pubmed-meshheading:8101218-Pain Measurement, pubmed-meshheading:8101218-Parasympathomimetics, pubmed-meshheading:8101218-Pirenzepine, pubmed-meshheading:8101218-Rats, pubmed-meshheading:8101218-Rats, Sprague-Dawley, pubmed-meshheading:8101218-Receptors, Adrenergic, alpha, pubmed-meshheading:8101218-Receptors, Muscarinic, pubmed-meshheading:8101218-Receptors, Opioid, pubmed-meshheading:8101218-Receptors, Serotonin, pubmed-meshheading:8101218-Spinal Cord, pubmed-meshheading:8101218-Time Factors, pubmed-meshheading:8101218-Tissue Distribution
pubmed:year
1993
pubmed:articleTitle
Characterization of the antinociception produced by intrathecally administered muscarinic agonists in rats.
pubmed:affiliation
Department of Pharmacology, University of Kentucky College of Medicine, Lexington.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't